Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)
Sponsor: Axovant Sciences Ltd.
Listed as NCT02708186, this PHASE2 trial focuses on Dementia With Lewy Bodies and Parkinson's Disease Dementia and remains completed. Sponsored by Axovant Sciences Ltd., it has been updated 15 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2020 — Dec 2020 [monthly]
Completed PHASE2
-
Nov 2018 — Jun 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Feb 2018 [monthly]
Recruiting PHASE2
-
Mar 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Axovant Sciences Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .